EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022

Carla Rizzo iD, Sara Amata iD, Ivana Pibiri iD, Andrea Pace iD, Silvestre Buscemi, Antonio Palumbo Piccionello iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24097728 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Carla Rizzo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 17, 90128…. Hauptthemen laut MEDLINE: Heterocyclic Compounds. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PNR, Next Generation EU, PNRR, PNR: Next-Generation EU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities. This is demonstrated by the increasing number of newly synthesized fluorinated heterocyclic compounds among the Food and Drug Administration FDA-approved drugs. In this review, the biological activity, as well as the synthetic aspects, of 33 recently FDA-approved fluorinated heterocyclic drugs from 2016 to 2022 are highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic CompoundsPharmaceutical PreparationsFluorineChemistry, Pharmaceutical

Stichwörter der Autor:innen

FDA-approvedfluorineheterocycles

Substanzen

Pharmaceutical PreparationsHeterocyclic CompoundsFluorine

Autor:innen und Institutionen

  • Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze, Ed. 17, 90128 Palermo, Italy.

ORCID-Profile: Carla Rizzo, Sara Amata, Ivana Pibiri, Andrea Pace, Antonio Palumbo Piccionello

Förderung

  • PNR, Next Generation EU
  • PNRR
  • PNR: Next-Generation EU

Zitieren

APA

Rizzo, C., Amata, S., Pibiri, I., Pace, A., Buscemi, S., & Palumbo Piccionello, A. (2023). FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24097728

Vancouver

Rizzo C, Amata S, Pibiri I, Pace A, Buscemi S, Palumbo Piccionello A. FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24097728

BibTeX
@article{Rizzo2023,
  author = {Rizzo, Carla and Amata, Sara and Pibiri, Ivana and Pace, Andrea and Buscemi, Silvestre and Palumbo Piccionello, Antonio},
  title = {FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24097728}
}
Kostenlos starten →